Demographic and co-morbidity characteristics of patients tested for SARS-CoV-2
 from March 2020 to January 2022 in a national clinical research network: results
 from PCORnet[®]

400

- 401 Short Title: Characteristics of patients tested for SARS-CoV-2 in a national research network
- Jason P. Block, MD, MPH^{1*}; Keith A. Marsolo, PhD²; Kshema Nagavedu, MPH¹; L. Charles
- Bailey, MD, PhD³; Tegan K. Boehmer, PhD^{4, 5}; Julia Fearrington¹; Aaron M. Harris, MD,
- 404 MPH^{4,5}; Nedra Garrett, MS⁴; Alyson B. Goodman, MD, MPH^{4,5}; Adi V. Gundlapalli, MD, PhD,
- 405 MS⁴; Rainu Kaushal, MD, MPH⁶; Abel Kho, MD⁷; Kathleen M. McTigue, MD, MPH, MS⁸;
- 406 Vinit P. Nair, BPharm, MS⁹; Jon Puro, MPA/HA¹⁰; Elizabeth Shenkman, PhD¹¹; Mark G.
- 407 Weiner, MD³; Neely Williams, EdD¹²; Thomas W. Carton, PhD, MS¹³ on behalf of PCORnet[®]
- 408 Network Partners†
- ¹Department of Population Medicine, Harvard Pilgrim Health Care Institute, Harvard Medical
 School, Boston, Massachusetts, United States of America
- ²Department of Population Health Sciences, Duke University, Durham, North Carolina, United
 States of America
- 413 ³Applied Clinical Research Center, Department of Pediatrics, Children's Hospital of
- 414 Philadelphia, Philadelphia, Pennsylvania, United States of America
- ⁴US Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America
- 416 ⁵US Public Health Service, Rockville, Maryland, United States of America
- ⁶Department of Population Health Sciences, Weill Cornell Medicine, New York, New York,
 United States of America
- ⁷Center for Health Information Partnerships, Northwestern University, Chicago, Illinois, United
 States of America
- ⁸Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of
 America
- 423 ⁹PRACnet, Sharon, MA, United States of America
- 424 ¹⁰OCHIN, Inc., Portland, OR, United States of America
- ¹¹Health Outcomes & Biomedical Informatics, College of Medicine, University of Florida,
- 426 Gainesville, Florida, United States of America
- 427 ¹²Community Partners Network Inc, Nashville, Tennessee, United States of America
- 428 ¹³Louisiana Public Health Institute, New Orleans, LA, United States of America

430	
431	†Collaborative authors are listed in an Appendix
432	
433	*Corresponding author: jblock1@partners.org (JPB)
434	
435	
436	Abbreviations: EHR – electronic health record, CDM – Common Data Model, ETL – extract-
437	transfer-load procedure to move data from a clinical data warehouse to the PCORnet Common
438	Data Model; Arrhyth – arrhythmia, CAD – coronary artery disease, CHF – congestive heart
439	failure, CKD – chronic kidney disease, Chron pulm – chronic pulmonary disease, Coag –
440	Coagulopathy, DM2 – type 2 diabetes mellitus, HTN – hypertension, Mental – mental health
441	disorder; Amb – ambulatory care setting, ED –emergency department, Inpt – inpatient, Vent –
442	inpatient with procedure codes indicating use of mechanical ventilation; conv plasma –
443	convalescent plasma, dex – dexamethasone, HCO – hydroxychloroquine, remdes – remdesivir,
444	steroids – corticosteroids other than dexamethasone, tocili - tocilizumab
445	
446	Manuscript Word Count: 4096

447 Abstract Word Count: 413

448 Abstract

449

450 **Background**: Prior studies have documented differences in the age, racial, and ethnic

451 characteristics among patients with SARS-CoV-2 infection. However, little is known about how

- these characteristics changed over time during the pandemic and whether racial, ethnic, and age
- disparities evident early in the pandemic were persistent over time. This study reports on trends
- 454 in SARS-CoV-2 infections among U.S. adults from March 1, 2020 to January, 31 2022, using
- 455 data from electronic health records.
- 456 **Methods and Findings:** We captured repeated cross-sectional information from 43 large
- 457 healthcare systems in 52 U.S. States and territories, participating in PCORnet[®], the National
- 458 Patient-Centered Clinical Research Network. Using distributed queries executed at each
- 459 participating institution, we acquired information for all patients \geq 20 years of age who were
- 460 tested for SARS-CoV-2 (both positive and negative results), including care setting, age, sex,
- 461 race, and ethnicity by month as well as comorbidities (assessed with diagnostic codes).
- 462 During this time period, 1,325,563 patients had positive (13% inpatient) and 6,705,868 patients
- had negative (25% inpatient) viral tests for SARS-CoV-2. Disparities in testing positive were
- 464 present across racial and ethnic groups, especially in the inpatient setting. Compared to White
- 465 patients, Black or African American and other race patients had relative risks for testing positive
- of 1.5 or greater in the inpatient setting for 12 of the 23-month study period. Compared to non-
- 467 Hispanic patients, Hispanic patients had relative risks for testing positive in the inpatient setting
- of 1.5 or greater for 16 of 23. Ethnic and racial differences were present in emergency
- department and ambulatory settings but were less common across time than in inpatient settings.
- Trends in infections by age group demonstrated higher test positivity for older patients in the
- inpatient setting only for most months, except for June and July of 2020, April to August 2021,
- and January 2022. Comorbidities were common, with much higher rates among those
- hospitalized; hypertension (38% of patients SARS-CoV-2 positive vs. 29% for those negative)
- and type 2 diabetes mellitus (22% vs. 13%) were the most common.
- 475 **Conclusion and Relevance**: Racial and ethnic disparities changed over time among persons
- 476 infected with SARS-CoV-2. These trends highlight potential underlying mechanisms, such as
- 477 poor access to care and differential vaccination rates, that may have contributed to greater
- disparities, especially early in the pandemic. Monitoring data on characteristics of patients
 testing positive in real time could allow public health officials and policymakers to tailor
- 480 interventions to ensure that patients and communities most in need are receiving adequate
- 481 testing, mitigation strategies, and treatment.

Multiple studies have documented the substantial differences in characteristics of patients with 482 SARS-CoV-2 early in the pandemic, with individuals of minority race or ethnicity and older age 483 bearing a much higher burden of severe COVID-19 illness (1-4). The US Centers for Disease 484 Control and Prevention (CDC) has provided detailed information about cases and deaths by 485 demographic characteristics, over time, gathered from data provided by state and local health 486 487 departments and reference laboratories (5). These data have shown that rates of deaths per 100,000 spiked among non-Hispanic Black individuals early in the pandemic, followed by a 488 decline compared to other racial and ethnic groups in the Summer and Fall 2020 and another 489 490 increase starting in early 2021. Similarly, death rates among Hispanic individuals have remained higher than non-Hispanic individuals throughout the pandemic. However, to date, there has been 491 limited information about patient characteristics and disparities among COVID-19 patients 492 across care settings over time, compared to non-COVID-19 patients, such as those testing 493 negative for SARS-CoV-2. These comparisons can help determine whether characteristics of 494 patients and temporal trends were unique to patients with COVID-19 or were consistent with 495 trends among patients with other illnesses. Further, this information can foster understanding of 496 pandemic dynamics, both for ongoing public health response and to help determine how best to 497 498 prepare for future public health crises.

499

Analyzing trends over time across care settings requires availability of longitudinal information
on large populations throughout the entire course of the pandemic with detailed information
about individuals, which is typically not available from public health authorities and public
health departments. Research networks fill this void by using granular data from many healthcare
systems, providing real-world information on diverse populations, followed for long periods.

505	Funded by the Patient-Centered Outcomes Research Network® (PCORI®), PCORnet®, the
506	National Patient-Centered Clinical Research Network, is a network-of-networks that facilitates
507	research using electronic health record (EHR), administrative health plan claims, and other
508	healthcare data (6,7). PCORnet currently has participation from more than 60 data contributing
509	sites (i.e., individual health systems) embedded within nine Clinical Research Networks (8).
510	Using data from 23 months of the pandemic (March 2020 through January 2022) in 43
511	institutions participating in PCORnet, we describe demographic trends over time of one of the
512	largest US national sample of patients testing positive or negative for SARS-CoV-2.
513	
514	Methods
515	PCORnet [®] Common Data Model
516	PCORnet [®] operates as a distributed research network, where data are held locally behind
517	institutional firewalls, with queries sent to institutions from a central PCORnet® Coordinating
518	Center. The participating sites utilize the PCORnet® Common Data Model, in which each data
519	contributing site maps its clinical and/or administrative claims data into a standardized
520	representation (9). These data are normally updated quarterly by sites, coinciding with data
521	quality curation cycles in which data are examined for conformance with the Common Data
522	Model specifications as well as data plausibility and data completeness.
523	
524	Prompted by the COVID-19 pandemic, PCORnet® sites agreed to rapidly implement
525	supplemental data extraction/curation procedures to allow for rapid capture of information on
526	patients with COVID-19. Starting in early April 2020, sites began updating COVID-related data
527	at least monthly (as often as daily) instead of quarterly. Rather than doing this for all patients

528	(which requires considerable processing time and effort), PCORnet [®] sites included a subset of all
529	patients, including only those who had at least one International Classification of Diseases, 10th
530	revision, Clinical Modification (ICD-10-CM) diagnostic code for a potential viral illness,
531	including COVID-19, or had a lab result for a SARS-CoV-2 test recorded beginning January 1,
532	2020 (Supplemental Figure 1) (10). Through January 31, 2022, this database included

533 16,317,253 individual patients 20+ years of age.

534

535 *Queries and Patient Characterization*

536 From this larger population of patients, we used existing modular programs to characterize all patients tested for SARS-CoV-2 (Supplemental Methods Note). These programs return only 537 aggregate data from sites. Submission, and use of these data are covered by a PCORnet-wide 538 539 Data Sharing Agreement and individual site Institutional Review Board approvals for their PCORnet Common Data Model data. Using designated Logical Observation Identifiers Names 540 and Codes (LOINC) (11), we captured information on patients with results of "positive," 541 "presumptive positive," or "detected" on nuclear acid amplification (NAAT)/polymerase chain 542 reaction (PCR) or antigen viral tests for SARS-CoV-2 (referred to as "testing positive" or 543 "positive viral test" hereafter) as well as those with results of "negative ("testing negative" or 544 "negative viral test"). Patients included in the negative viral test strata had only records of 545 546 negative tests and no positive tests. We stratified patients based on the setting of their viral test: 547 1) all, 2) ambulatory, 3) emergency department, and 4) inpatient. The latter three categories were mutually exclusive. We assigned a care setting by determining the setting for encounters before 548 549 and after the test was performed (1 day before and 16 days following). To make care settings 550 exclusive, we removed patients from a lower care setting stratum if they had encounters in a

higher care setting (for ambulatory strata, we assessed emergency and inpatient encounters) 551 before and after their positive test (21 days before and 16 days following the date of the test) 552 (Supplemental Note). Patients identified as receiving care in the emergency department 553 included patients who were discharged directly from this setting and not admitted to the hospital 554 within 16 days; those admitted directly from the emergency department or soon thereafter were 555 556 characterized with the inpatient care setting cohort. One-third of patients did not have a care setting associated with their positive test, perhaps because many patients were tested in drive-557 thru testing settings that might not have registered an encounter; some of these tests might also 558 559 have been ordered during telehealth or virtual visits that were not specifically assessed in our queries. We captured all information with respect to the date for an index viral laboratory test, 560 which was the first positive test for patients testing positive and the first negative test for patients 561 562 testing negative. All codes for case definitions, comorbidities, treatments, and labs were posted on GitHub. 563

564

565 Demographics, Comorbidities, and Disease Severity

Using information available at the time of the test, we assessed demographic characteristics of 566 567 patients (i.e., age group, sex, race, and ethnicity) using value sets defined in the PCORnet Common Data Model. Sex categories allowed for Male, Female, and Other. Several race 568 569 categories (i.e., Multiple race, Other race, Native Hawaiian/Other Pacific Islander, and Alaskan 570 Native/American Indian) were less common and typically <1% for all strata; these were grouped together under "Other Race." Ethnicity was defined as Hispanic or not Hispanic, with a separate 571 missing category. We assessed monthly trends by age group, race, and ethnicity by care setting. 572 573 We assessed disparities by calculating monthly patient positivity as the total number of patients

testing positive separately for each racial, ethnic and age group, divided by the total number of patients tested in that month by care setting. We calculated relative risks (RRs) by month as the percentage of patients testing positive by racial, ethnic, and age group divided by the percentage in a reference group (White; non-Hispanic; age 20-39 years, respectively for each assessment of patient characteristics); these calculations were done separately for race, ethnicity, and age. We noted that disparities were present when RRs were ≥ 1.5 .

580

We included a detailed assessment of comorbidities, which were selected based on information 581 582 presented in publications regarding the association of comorbidities with COVID-19 outcomes (12–15). Patients were considered to have a comorbidity if they had at least two ICD-9-CM or 583 ICD-10-CM codes for the disease/condition recorded any time over a three-year period prior to 584 585 the index date of their viral test. We also captured use of critical care procedure/billing Current Procedural Terminology (CPT) codes (99291, 99292) during this period and mechanical 586 ventilation usage through presence of ICD-10-CM, Healthcare Common Procedure Coding 587 System (HCPCS) and CPT codes any time from the index date of the SARS-CoV-2 test through 588 21 days after the index date. Lastly, we categorized weight status using the most recent height 589 590 and weight available within the year prior to the index date. This study was reviewed by the Institutional Review Board of Harvard Pilgrim Health Care, Inc., which deemed it exempt from 591 review because it was a public health surveillance project, conducted under the direction of a 592 593 public health authority. This activity was reviewed by the CDC and was conducted consistent with applicable federal law and CDC policy. 594

595

596

597 Results

598 Characteristics of patients testing positive for SARS-CoV-2

- 599 The query captured aggregate data on 1,325,563 patients who tested positive for SARS-CoV-2
- and 6,705,868 patients who tested negative from March 1, 2020 through January 31, 2022.
- Across the 43 sites, percent contributions to the overall sample ranged from <1% to 15% with 15
- sites each contributing \geq 3% of the total; these 15 sites included 73% of all patients testing
- positive for SARS-CoV-2. Of patients testing positive, 38% were treated in the ambulatory
- setting, 15% were seen and discharged from the emergency department, and 13% were
- hospitalized (**Table 1**). Among hospitalized patients, 10% and 19% were documented as
- receiving mechanical ventilation and critical care treatment, respectively. Test positivity among
- patients (not tests) was 17% overall and 15%, 20%, and 9% in the ambulatory, emergency
- 608 department, and inpatient setting, respectively.
- 609

Black or African American patients were 16% of all patients testing positive but were 12%, 28%, 610 and 23% of patients testing positive in the ambulatory, emergency department, and inpatient 611 settings, respectively (Table 1). Other Race patients were 10% of all patients testing positive but 612 were 8%, 16%, and 15% in the ambulatory, emergency department, and inpatient settings. The 613 RR for testing positive for Black or African American patients vs. White patients was 1.0, 1.2, 614 615 and 1.5 across the care settings, and RR for Other Race patients was 1.1, 1.3, and 1.8 (Table 1). 616 Compared to non-Hispanic patients, the RR for testing positive in the ambulatory, emergency department, and inpatient settings for Hispanic patients was 1.5, 1.5, and 1.8 (Table 1). 617

618

619	Overall, more	patients testing	g positive were	in the 20 to 39	years age group	(41%) than other age
	,					

- groups, primarily driven by patients testing positive in the ambulatory setting (Table 1). Patients
- 621 20-39 years of age comprised the largest proportion of patients testing positive in the ambulatory
- and emergency department settings, but 55-74 year old patients comprised the largest proportion
- 623 in the inpatient setting (Table 1). Compared to patients who were 20-39 years, the RR for testing
- positive in the inpatient setting was 1.7 for patients 40 to <55 years, 1.8 for patients 55 to <65
- years, 1.7 for patients 65 to <75 years, 1.9 for patients 75-<85 years, and 2.2 for patients 85+
- 626 years. Women comprised a larger proportion of patients testing positive overall (56%), with men
- more likely to test positive only in the inpatient setting (RR 1.4).

Fig 1. Monthly relative risks for testing positive for SARS-CoV-2 by race and ethnicity and care setting, March 1, 2020 to January 31, 2022.

These figures show the relative risk for testing positive by month for Black or African American, 630 Asian, Other Race or Missing Race compared to White race as a reference in the (A) ambulatory 631 or (B) inpatient setting and those who were Hispanic, or had Missing Hispanic ethnicity 632 compared to Not Hispanic as a reference in the (C) ambulatory or (D) inpatient setting. Care 633 settings are mutually exclusive. Proportions of patients testing positive by care setting are 634 available in Supplemental Figures 2 and 4; relative risks for testing positive in the emergency 635 department are available in Supplemental Figures 3 and 5. Abbreviations: Hisp-Hispanic; Not 636 Hisp-Not Hispanic; Miss-Missing. 637

638

639 *Trends by race, ethnicity, and age*

Disparities by race were most apparent during the early phase of the pandemic, especially in the

- 641 inpatient setting. Among patients hospitalized with SARS-CoV-2 in March and April 2020,
- Black or African American, Other race, and White patients comprised nearly an equal proportion
- of patients (Supplemental Figure 2). Black or African American patients still comprised more
- than 20% of patients hospitalized for 17 of the 23 months examined. When we calculated relative
- risks by month, we demonstrated that hospitalized Black or African American patients were
- twice as likely to test positive for SARS-CoV-2 compared to White hospitalized patients from

647	April through August 2020 and 1.5 times as likely to tested positive for 12 of the 23 months,
648	with the lowest RRs from September 2020 to January 2021 and again from June to November
649	2021 (Figure 1). Patients with "Other Race" had similar patterns when compared to patients of
650	White race, with relative risks of 1.5 or greater for 12 of the 23 months. Patients with Missing or
651	Asian race followed a similar pattern to Black and Other Race groups early in the pandemic and
652	from December 2020 through April 2021. These disparities were similar in the emergency
653	department, with lower relative risks than the inpatient setting (Supplemental Figure 3).
654	Disparities also were noted in the ambulatory setting but only in the early months of the
655	pandemic (Figure 1).
656	
657	Trends were similar when examined by ethnicity, with a disproportionate number of patients
658	with Hispanic ethnicity testing positive across all care settings; these disparities persisted through
659	mid-2021 in the emergency department in inpatient settings (Figure 1; Supplemental Figures
660	4-5). Compared to non-Hispanic patients, Hispanic patients had relative risks for testing positive
661	in the inpatient setting of 1.5 or greater for 16 months.
662 663 664 665 666 667 668 669	Fig 2. Monthly relative risks for testing positive for SARS-CoV-2 by age group and care setting, March 1, 2020 to January 31, 2022. These figures show the relative risks for testing positive by month and age group in the (A) ambulatory and (B) inpatient setting; reference was 20-39 years of age. Proportions of patients testing positive by care setting are available in Supplemental Figure 6; relative risks for testing positive in the emergency department are available in Supplemental Figure 7. Care settings are mutually exclusive.
670	Trends in infections by age demonstrated consistently higher test positivity for 20-39-year-olds
671	in the ambulatory setting (Figure 2, Supplemental Figures 6-7). In the emergency department,
672	younger patients were more likely to test positive than older patients in most months except for
673	March to April 2020 (Supplemental Figure 7). Patients in older age groups (55 years and

higher) were more likely to test positive in the inpatient setting than patients who were 20-39 674 years, with RRs \geq 1.5 consistently except in June-July 2020, April-July 2021, and December 675 2021-January 2022 (Figure 2, Supplemental Figure 6); patients who were 40 to 54 years had 676 RRs \geq 1.5 for nearly all months of the pandemic compared to patients 20-39 years, except 677 December 2021-January 2022. 678 679 *Comorbidities* 680 Among patients testing positive for SARS-CoV-2, hypertension was the most common 681 comorbidity (19% for all patients) followed by type 2 diabetes (DM2) (9%), chronic pulmonary 682 disease (7%), and mental health disorders (8%); 7% of patients had hypertension and either Type 683 1 (T1DM) or T2DM (Figure 3; Supplemental Table 3). These diagnoses were more common 684 among patients with SARS-CoV-2 treated in the inpatient setting, with hypertension present in 685 38% and DM2 in 22% (19% had hypertension and either DM1 or DM2) of inpatients. The 686 687 prevalence of obesity also was high at 46% among all patients testing positive but was similar across care settings (45% to 48%). Patients testing negative while inpatient had a lower 688 prevalence of hypertension (29% vs. 38%), diabetes (13% vs. 22%), and obesity (41% vs. 47%) 689 690 compared with those testing positive (Supplemental Table 4); prevalence was similar for coronary artery disease (10% vs. 13%), mental health disorders (11% vs. 12%), or chronic 691 pulmonary disease (11% vs. 14%). 692 693 Fig 3. Comorbidities for patients with positive viral tests for SARS-CoV-2 across care settings, March 1, 2020 to January 31, 2022. 694

These figures show prevalence of various comorbidities for patients with positive viral tests for SARS-CoV-2 across care settings. Each condition includes a broad capture of ICD-9-CM and ICD-10-CM codes, with codes lists available on Github. For example, mental health codes include those for a large number associated with psychotic and mood disorders. Care settings were mutually exclusive. Abbreviations: AV-ambulatory visit; ED-emergency department; IP-

inpatient or hospitalized; HTN-hypertension; DM2-diabetes mellitus type 2, DM-diabetes

mellitus Types 1 and2, Arrhyth-Arrhythmia; Chron Pulm-Chronic Pulmonary Disease; CAD coronary artery disease; CKD-chronic kidney disease; MH Dis-mental health disease; CHF congestive heart failure.

704

705 **Discussion**

Using real world electronic health care data, we examined a large population of patients with

707 SARS-CoV-2 infection, using information on 1.3 million in 43 institutions testing positive for

SARS-CoV-2 infection and 6.7 million who tested negative without any positive tests through

January 2022. Unlike most other studies, we compared patients across care settings, with rich

demographic and comorbidity data by ambulatory, emergency department, and inpatient settings;

711 we also compared patients who tested positive to those who tested negative. Trends by race,

ethnicity and age revealed important information about health inequities during the COVID-19

713 pandemic. While variable over time, individuals who were Black or African American or

Hispanic were more likely to test positive compared to White and non-Hispanic patients in the

715 inpatient setting for most months.

716

717 Beyond basic demographic trends in cases and death overall, as reported by public health authorities, few studies have reported demographic trends in infections. Studies that have 718 reported on these trends have covered short-term trends early in the pandemic; this study covers 719 720 23 months of the pandemic. Using data from a national reference laboratory (ARUP Laboratories, with nearly half of the sample of 19,320 patients from Utah), investigators at the 721 US Centers for Disease Control and Prevention (CDC) found a changing age distribution of 722 723 patients infected with SARS-CoV-2, with a decline in median age in June and July 2020 of 35.8 years compared to 40.5 in March and April 2020 (16). From May to August 2020, state 724 725 electronic laboratory reporting data from 37 states showed similar trends by age, with 20-to-29-

year-olds having the highest incidence of SARS-CoV-2 among all age groups from June through
August (4). This increase in incidence among young people continued through early September,
as 18- to 22-year-olds started to return to colleges (3). In our study, we found peaks in test
positivity of young people during the Summer of 2020 and 2021.

730

In our study, racial and ethnic disparities in infections, especially among those hospitalized, were 731 evident throughout the pandemic but were most evident early in the pandemic. Disparities by 732 race, defined by test positivity, in the inpatient setting were highest early in the pandemic and 733 734 during the Winters of 2020/21 and 2021/22. Ethnic disparities were persistent for most of the pandemic in the inpatient setting, with a higher proportion of Hispanic individuals testing 735 positive when hospitalized compared to non-Hispanic patients; this trend ended in Fall 2021. 736 737 Other studies have found similar patterns for shorter periods. In COVID-19 mortality data from the National Vitals Statistics System, disparities were evident from May to August 2020, with 738 some differences over time (1). Overall, 19% of individuals who died from COVID-19 were 739 Black or African American, with a reduction in proportion from 20% in May 2020 to 17% in 740 August: 24% of all people who died were Hispanic, with an increase from 16% to 26% during 741 this same time period. From January 26 to October 3, 2020, there were nearly 300,000 excess 742 deaths in the United States; this rate summarizes all-cause mortality compared to expected rates 743 744 from prior years, in this case 2015 to 2019 (2). Substantial disparities were present. The excess 745 death rate was 11.9% for Whites but 29% to 37% for racial minorities and 53% for Hispanic persons; this was highest in March and April 2020 with a second peak among Hispanics in July 746 747 and August 2020.

748

Among all conditions assessed, we found higher prevalence of hypertension, type 2 diabetes 749 mellitus, and obesity among adults treated in the inpatient setting with SARS-CoV-2 compared 750 to those testing negative. These differences could reflect the demographic differences, including 751 age, found between those testing negative and positive or an increased risk of severe disease 752 among patients with these conditions. Diabetes has been found to be an independent risk factor 753 754 for severe COVID-19, including mortality, likely secondary to underlying physiologic mechanisms, such as immune effects from diabetes and a higher affinity for cellular binding of 755 the virus in patients with diabetes (17–20). The high prevalence of diabetes especially in our 756 757 study is further evidence of a greater burden of severe SARS-CoV-2 in this population. 758 COVID-19 surveillance in PCORnet provides several unique opportunities. Obtaining real-759 760 world, comprehensive information on a diverse, national population of patients with COVID-19 is critical to help guide policymakers as well as clinical and public health leaders regarding 761 planning for future COVID-19 response. The network infrastructure and large samples allows for 762 creation of research-ready cohorts and in-depth assessment of patients, based on demographic or 763 clinical characteristics. Analyses can be done in a distributed fashion without sharing patient-764 level data, including predictive modeling, and aggregation across diverse sites can increase 765 generalizability. Large sample sizes with granular clinical information will be increasingly 766 767 important to capture information on patient subgroups, defined by demographics or less common 768 presentations or outcomes of COVID-19, such as rare complications of SARS-CoV-2. Prior PCORnet surveillance studies have examined disparities in use of monoclonal antibodies (21), 769 770 the occurrence of post-acute sequelae of COVID-19 (22), and the incidence of myocarditis and 771 pericarditis after SARS-CoV-2 infection and COVID-19 vaccination (23). The investment in

772	changing the processes for data management – moving to frequent updates for patients with
773	respiratory illnesses from a quarterly update – prepared the network to make ongoing
774	contributions to the investigation of COVID-19. Other national initiatives, such as The National
775	COVID Cohort Collaborative (N3C) are gathering similar information from institutions, with
776	patient-level data extracts, to allow for varied research on COVID-19 over time (24).
777	
778	Limitations
779	Several limitations are inherent to working with structured healthcare data. First, electronic
780	health records and administrative claims data may not have complete data on some patients,
781	especially patients tested and treated entirely outside of a PCORnet health system or outside of
782	the health plan insurance coverage. In such cases, the PCORnet Common Data Model may not
783	have any information about a SARS-CoV-2 infection or inadequate information on chronic
784	diseases and medication use. For example, some institutions had less data on symptomatic
785	ambulatory patients, who may have been referred to outside facilities for testing; other
786	institutions did their own testing for symptomatic ambulatory patients. Most importantly,
787	missing information could have led to misclassification, such as when a patient only had
788	negative tests in the healthcare system but tested positive at an outside institution or on a home
789	test, results that would not be captured in the PCORnet Common Data Model. If missingness
790	was differential by demographic characteristics, proportions reported could be inaccurate.
791	Second, even for patients who received all care within a PCORnet institution, missing data were
792	still possible, as we found for variables such as race, weight status, and care setting. If
793	missingness was non-random, which could be the case if data were less available on patients of
794	certain race categories, our results could provide some incomplete conclusions. Third, the results

795 we report are descriptive and unadjusted for potential confounders. We discovered higher rates of several chronic conditions among patients with SARS-CoV-2 compared to those without; 796 these differences might be explained by demographic or age differences. We required at least 797 two ICD-10-CM codes for chronic conditions, which may have led to an undercount, especially 798 799 for those patients who were not seen often in the healthcare system prior to their SARS-CoV-2 800 test. Fourth, we report differences based on race/ethnicity information available in the EHR. We do not have further information in the Common Data Model, such as socioeconomic status or 801 other information that underlie disparities, such as exposure to racism or other social 802 803 determinants. We also do not have access to payer status, which could provide some information on disparities by type of insurance, such as governmental or private. Finally, PCORnet does not 804 allow for representative estimates of overall COVID-19 cases across the U.S. Because PCORnet 805 806 has a fixed number of institutions and is not designed to be representative of the U.S. population, the prevalence of cases across states in PCORnet is not equivalent to the actual state prevalence 807 of patients who have been tested for SARS-CoV-2. 808

809

810 *Conclusion*

PCORnet has captured information on one of the largest samples to date of patients tested for
SARS-CoV-2 infection. Racial and ethnic minority patients have borne a disproportionate
burden of the pandemic, making up a larger proportion of those infected than other groups,
especially for those hospitalized. Monitoring these data in real time could allow public health
officials and policymakers to develop messaging and targeted programs for these communities to
ensure that they are receiving adequate testing, mitigation strategies, and treatment. Patients

- 817 diagnosed with COVID-19 were found to have a high burden of underlying conditions,
- 818 especially among those hospitalized.

820 Acknowledgement

821 This study was funded through a cooperative agreement to the Task Force for Global Health,

- through the US Centers for Disease Control and Prevention: COVID-19 Electronic Healthcare
- Data Initiative. Each of the institutions received funding through this agreement.

824 The Clinical Research Networks and Coordinating Center reported in this publication are

825 Network Partners in PCORnet, the National Patient-Centered Clinical Research Network.

PCORnet has been developed with funding from the Patient-Centered Outcomes Research

- 827 Institute (PCORI). The Network Partners' participation in PCORnet is funded through the
- following PCORI Awards: Coordinating Center (PCORI-CC2-Duke-2016); ADVANCE (RI-
- 829 CRN-2020-001); CaPriCORN (RI-CRN-2020-002); GPC (RI-CRN-2020-003); HealthCore (HP-
- 830 1510-32545); Insight (RI-CRN-2020-004); OneFlorida (RI-CRN-2020-005); PaTH (RI-CRN-
- 831 2020-006); PEDSnet (RI-CRN-2020-007); REACHnet (RI-CRN-2020-008); and, STAR (RI-
- 832 CRN-2020-009). Authors report no competing interests associated with this publication.
- 833 The funder provided support in the form of salaries or stipends for all authors. As the funding

organization of the network infrastructure for PCORnet, PCORI participates in discussions and

high-level decision-making about the network and its strategic priorities. With this participation,

836 PCORI provided support and approval for the initiative to alter the PCORnet infrastructure and

support queries related to COVID-19. However, PCORI but had no specific role in the study

- design, data collection and analysis, decision to publish, or preparation of the manuscript. The
- specific roles of these authors are articulated in the 'author contributions' section.
- 840 The findings and conclusions in this report are those of the authors and do not necessarily
- represent the official position of CDC or the US Public Health Service.
- 842

843

844 Collaborative Authors: *PCORnet[®] Network Partners*

Faraz S. Ahmad, MD, MS, Northwestern University Feinberg School of Medicine; Saul Blecker, 845 NYU Grossman School of Medicine; H. Ryan Carnahan, PharmD, MS, The University of Iowa 846 College of Public Health, Department of Epidemiology; Olveen Carrasquillo, MD, MPH, 847 University of Miami Miller School of Medicine; Bernard P. Chang, MD, PhD, Columbia 848 University Irvine Medical Center; Katherine Chung-Bridges, MD, MPH, Health Choice 849 Network; Lindsay G. Cowell, MS, PHD, UT Southwestern Medical Center; Janis L. Curtis, 850 MSPH, MA, Duke University School of Medicine; Christine Draper, Department of Population 851 Medicine, Harvard Pilgrim Health Care Institute, Harvard Medical School; Soledad A. 852 Fernandez, PhD, The Ohio State University; Christopher B. Forrest, MD, PhD, Children's 853 854 Hospital of Philadelphia; Nidhi Ghildayal, PhD, Department of Population Medicine, Harvard Pilgrim Health Care Institute, Harvard Medical School; David A Hanauer, MD, MS, University 855 of Michigan; Rachel Hess, MD, MS, University of Utah; Benjamin D. Horne, PhD, MStat, MPH, 856 Intermountain Medical Center Heart Institute, Stanford University School of Medicine; Philip 857 858 Giordano, MD, FACEP, Orlando Health, Inc.; William Hogan, MD, MS, University of Florida; Wenke Hwang, PhD, Penn State University College of Medicine; Harold P. Lehmann MD, 859

- PhD, Johns Hopkins School of Medicine; Abel Kho, MD, MS, Northwestern University; Scott
- 861 Mackey, DO, LCMC Health; Kenneth H. Mayer MD, Fenway Health; Narayana Mazumder, MS,
- Allina Health; James C. McClay, MD, University of Nebraska Medical Center; J. Greg Merritt,
- PhD, Patient is Partner, LLC; Abu Saleh Mohammad Mosa, Phd, MS, FAMIA, University of
- 864 Missouri; Samyuktha Nandhakumar, MS, North Carolina Translational and Clinical Sciences
- 865 Institute, UNC School of Medicine; Bridget Nolan, Department of Population Medicine, Harvard
- Pilgrim Health Care Institute; Jihad S. Obeid, MD, FAMIA, Medical University of South
- 867 Carolina; Brian Ostasiewski, Wake Forest School of Medicine; Anuradha Paranjape, MD, MPH,
- Lewis Katz School of Medicine at Temple University; Lav Parshottambhai Patel, BS, MS,
- 869 University of Kansas Medical Center; Patricia S. Robinson, PhD, APRN, AdventHealth
- 870 Research Institute; Alexander Stoddard, MS, CTSI, Medical College of Wisconsin; William E.
- Trick, Cook County Health; Russell L. Rothman, MD, MPP, Vanderbilt University Medical
- 872 Center; Neely Williams, MDiv, EdD

874	References
875	iterer energy
876	1. Gold JAW. Rossen LM. Ahmad FB. Sutton P. Li Z. Salvatore PP. et al. Race. Ethnicity.
877	and Age Trends in Persons Who Died from COVID-19 - United States, May-August 2020.
878	MMWR Morbidity and mortality weekly report. 2020;69(42):1517-21.
879	2. Rossen LM, Branum AM, Ahmad FB, Sutton P, Anderson RN. Excess Deaths
880	Associated with COVID-19, by Age and Race and Ethnicity - United States, January 26-October
881	3, 2020. MMWR Morbidity and mortality weekly report. 2020;69(42):1522-7.
882	3. Salvatore PP, Sula E, Coyle JP, Caruso E, Smith AR, Levine RS, et al. Recent Increase in
883	COVID-19 Cases Reported Among Adults Aged 18-22 Years - United States, May 31-
884	September 5, 2020. MMWR Morbidity and mortality weekly report. 2020;69(39):1419-24.
885	4. Boenmer TK, Devies J, Caruso E, van Santen KL, Tang S, Black CL, et al. Changing Age Distribution of the COVID 10 Pendemia United States May August 2020 MMWP
000 997	Morbidity and mortality weekly report 2020:69(39):1404-9
888	5 CDC COVID data tracker 2021 [Available from: https://covid.cdc.gov/covid-data-
889	tracker/#demographicsovertime
890	6. Collins FS, Hudson KL, Briggs JP, Lauer MS. PCORnet: turning a dream into reality.
891	Journal of the American Medical Informatics Association : JAMIA. 2014;21(4):576-7.
892	7. Fleurence RL, Curtis LH, Califf RM, Platt R, Selby JV, Brown JS. Launching PCORnet,
893	a national patient-centered clinical research network. Journal of the American Medical
894	Informatics Association : JAMIA. 2014;21(4):578-82.
895	8. Forrest C, McTigue K, Hernandez A, Cohen L, Cruz H, Haynes K, et al. PCORnet 2020:
896	current state, accomplishments, and future directions. Submitted for publication. 2020.
897	9. Greene DN, Jackson ML, Hillyard DK, Delgado JC, Schmidt KL. Decreasing median age
898	one 2020:15(10):e0240783
900	10 Qualls LG Phillips TA Hammill BG Topping I Louzao DM Brown IS et al
901	Evaluating Foundational Data Quality in the National Patient-Centered Clinical Research
902	Network (PCORnet(R)). EGEMS (Washington, DC). 2018;6(1):3.
903	11. International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-
904	CM) 2020 [Available from: https://www.cdc.gov/nchs/icd/icd10cm.htm.
905	12. Fu L, Wang B, Yuan T, Chen X, Ao Y, Fitzpatrick T, et al. Clinical characteristics of
906	coronavirus disease 2019 (COVID-19) in China: A systematic review and meta-analysis. The
907	Journal of infection. 2020.
908	13. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of
909	Coronavirus Disease 2019 in China. The New England journal of medicine. 2020;382(18):1/08-
910 011	20. 14 Liang WH Guan WI Li CC Li VM Liang HP. Zhao V at al Clinical characteristics
911	and outcomes of hospitalised nationts with COVID-19 treated in Hubei (enicenter) and outside
913	Hubei (non-enicenter): A Nationwide Analysis of China The European respiratory journal
914	2020.
915	15. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al.
916	Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized
917	With COVID-19 in the New York City Area. Jama. 2020.
918	16. Muniyappa R, Gubbi S. COVID-19 pandemic, coronaviruses, and diabetes mellitus.
919	American journal of physiology Endocrinology and metabolism. 2020;318(5):E736-e41.

17. Barron E, Bakhai C, Kar P, Weaver A, Bradley D, Ismail H, et al. Associations of type 1

and type 2 diabetes with COVID-19-related mortality in England: a whole-population study. The
 lancet Diabetes & endocrinology. 2020;8(10):813-22.

18. Holman N, Knighton P, Kar P, O'Keefe J, Curley M, Weaver A, et al. Risk factors for

COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a populationbased cohort study. The lancet Diabetes & endocrinology. 2020;8(10):823-33.

926 19. Navaratnam AV, Gray WK, Day J, Wendon J, Briggs TWR. Patient factors and temporal

- trends associated with COVID-19 in-hospital mortality in England: an observational study using
 administrative data. The Lancet Respiratory medicine. 2021;9(4):397-406.
- 929 20. Helms J, Kremer S, Merdji H, Clere-Jehl R, Schenck M, Kummerlen C, et al. Neurologic
 930 Features in Severe SARS-CoV-2 Infection. The New England journal of medicine. 2020.
- 21. Weiland NL, S. Zimmer, C. U.S. calls for pause on Johnson & Johnson vaccine after
- 932 clotting cases. New York Times. 2021 13 April 2021.
- 933 22. Haendel MA, Chute CG, Bennett TD, Eichmann DA, Guinney J, Kibbe WA, et al. The
- National COVID Cohort Collaborative (N3C): Rationale, design, infrastructure, and deployment.
- Journal of the American Medical Informatics Association : JAMIA. 2021;28(3):427-43.

936

Table 1: Characteristics of patients positive for SARS-CoV-2 on polymerase chain reaction or antigen laboratory tests, March 1, 2020
 January 30, 2022, 43 PCORnet Data Contributing Institutions

	All SARS-CoV-2 +			SARS-CoV-2 +, Ambulatory			SARS-CoV-2 +, Emergency Department			SARS-CoV-2 +, Inpatient		
	1,325,563			499,370			202,241			172,673		
	N	%	RR	Ν	%	RR	Ν	%	RR	N	%	RR
Age (years)												
20-<40	540,033	41%	Ref	221,535	44%	Ref	85,360	42%	Ref	31,125	18%	Ref
40-<55	346,074	26%	1.0	138,259	28%	0.9	53,762	27%	1.0	33,280	19%	1.7
55-<65	204,153	15%	0.8	74,873	15%	0.6	29,682	15%	0.9	34,186	20%	1.8
65-<75	135,503	10%	0.6	43,829	9%	0.5	18,926	9%	0.7	34,580	20%	1.7
75-<85	70,592	5%	0.6	17,017	3%	0.4	10,162	5%	0.6	25,748	15%	1.9
85+	29,208	2%	0.7	3,857	1%	0.4	4,349	2%	0.5	13,754	8%	2.2

Sex												
Female	736,587	56%	Ref	284,413	57%	Ref	112,905	56%	Ref	86,107	50%	Ref
Male	588,459	44%	1.1	214,851	43%	1.0	89,312	44%	1.0	86,545	50%	1.4
Other ⁶	511	0%	*	102	0%	*	24	0%	*	20	0%	*
Race												
Asian	37,423	3%	0.9	13,153	3%	0.9	4,935	2%	1.0	5,594	3%	1.2
Black or African American	214,540	16%	1.1	62,218	12%	1.0	56,796	28%	1.2	39,384	23%	1.5
White	831,180	63%	Ref	343,881	69%	Ref	100,859	50%	Ref	91,793	53%	Ref
Other	126,993	10%	1.1	38,029	8%	1.1	32,338	16%	1.3	26,716	15%	1.8
Missing	115,427	9%	1.0	42,089	8%	1.2	7,313	4%	1.1	9,186	5%	1.5

Hispanic Ethnicity													
Yes	217,931	16%	1.5	69,250	14%	1.5	45,620	23%	1.5	33,254	19%	1.8	
No	937,127	71%	Ref	370,700	74%	Ref	139,387	69%	Ref	126,686	73%	Ref	
Other/Missing	170,505	13%	0.9	59,420	12%	0.9	17,234	9%	1.2	12,733	7%	1.2	
Month													
March 2020	19,823	1%		4,121	1%		4,007	2%		7,157	4%		
April 2020	39,561	3%		10,117	2%		6,257	3%		13,462	8%		
May 2020	25,207	2%		9,416	2%		4,989	2%		4,849	3%		
June 2020	36,650	3%		16,635	3%		6,045	3%		4,559	3%		
July 2020	60,330	5%		28,146	6%		8,698	4%		7,299	4%		
August 2020	37,832	3%		18,200	4%		4,552	2%		4,915	3%		
September 2020	34,122	3%		19,109	4%		3,247	2%		3,897	2%		

October 2020	60,474	5%	26,828	5%	6,386	3%	6,178	4%	
November 2020	125,513	9%	48,605	10%	13,789	7%	11,149	6%	
December 2020	131,017	10%	46,042	9%	14,255	7%	14,713	9%	
January 2021	97,096	7%	31,522	6%	12,466	6%	14,481	8%	
February 2021	39,816	3%	12,239	2%	5,749	3%	7,972	5%	
March 2021	32,802	2%	9,016	2%	5,905	3%	6,889	4%	
April 2021	32,097	2%	8,490	2%	6,735	3%	6,499	4%	
May 2021	15,190	1%	3,993	1%	3,631	2%	3,488	2%	
June 2021	8,414	1%	2,555	1%	1,815	1%	2,118	1%	
July 2021	22,919	2%	7,511	2%	6,776	3%	4,420	3%	
August 2021	62,668	5%	22,775	5%	14,955	7%	9,832	6%	
September 2021	52,779	4%	20,113	4%	10,079	5%	7,964	5%	

October 2021	33,004	2%	12,400	2%	5,478	3%	5,130	3%	
November 2021	35,651	3%	13,750	3%	6,220	3%	4,654	3%	
December 2021	109,629	8%	42,197	8%	21,346	11%	7,857	5%	
January 2022	212,969	16%	85,590	17%	28,861	14%	13,191	8%	

Figure 1: Relative Risks by Race and Ethnicity of Patients with Positive SARS-CoV-2 Test Result, by Care Setting and Month, March 2020—January 2022



A. Relative Risks by Race among SARS-CoV-2 Positive Patients in Ambulatory Setting





948 949

950 C. Ethnicity Distribution among SARS-CoV-2 Positive Patients in Ambulatory Setting



952

D. Ethnicity Distribution among SARS-CoV-2 Positive Patients in Inpatient Setting



955

956 Figure 2: Age Distribution of Patients with Positive SARS-CoV-2 Test Result, by Care

957 Setting and Month, March 2020—January 2022



958 A. Age Distribution of SARS-CoV-2 Positive Patients in Ambulatory Setting





961 962

963 Figure 3: Presence of Comorbidities among Patients Tested for SARS-CoV-2, by Care Setting and

964 Month, March 2020—January 2022



965 A. Patients Testing Positive for SARS-CoV-2

966 967

B. Patients Testing Negative for SARS-CoV-2



969

970 Captions for Supporting Information

- 971 S Methods Note: Describes process of code list generation, COVID-19 code-based case
- 972 definitions, and sensitivity analyses for the assessment of comorbidities
- 973

975

- 974 S1 Table: Responding PCORnet Healthcare Institutions
- 976 S2 Table: Characteristics of Patients Testing Negative for SARS-CoV-2 with No Positive
- 977 Tests, March 1, 2020 to January 31, 2022
- 978 S3 Table: Comorbidities among Patients SARS-CoV-2 +, by Care Setting
- 980 S4 Table: Comorbidities among Patients SARS-CoV-2 -, by Care Setting
- 981

979

- 982 S Figures
- 983

984 S Fig 1. PCORnet Common Data Models, including standard and COVID-19 Common 985 Data Model.

- The PCORnet Common Data Model includes information collected through various clinical data
 systems, including electronic health records (EHR) and health insurance claims or pharmacy
 dispensing records. Once data are entered by the user, systems transfer data to a data warehouse
 that is unique to their own health system and system vendor (e.g., Epic, Cerner). The typical
 process for populating the PCORnet Common Data Model is through an extraction-transferloading (ETL) procedure that allows for transformation of raw information into a form that is
 compliant with the Common Data Model specifications. This transformation, which is done by
- each individual institution in keeping with PCORnet's federated data infrastructure, allows for
- consistency across health systems and centralized querying of data, and the PCORnet ETL and
- 995 Common Data Model data refresh occurs quarterly. The PCORnet COVID-19 Common Data
- 996 Model utilizes a similar process but rather than including information on all patients, it includes
- information only on patients who have had at least one respiratory illness diagnostic code or a
 lab test ordered for SARS-CoV-2 since January 1, 2020. This process occurs frequently (as often
- as daily) and includes data with lag times between 1 day to 7 days, depending on the site.
- 1000

S Fig 2. Monthly Proportion of Patients Testing Positive for SARS-CoV-2 by Race and Care Setting

- These figures show the proportion of patients by month who were White, Black or African
 American, Asian, Other Race or Missing Race in the (A) Ambulatory, (B) Emergency
 Department, (C) Inpatient, and (D) Non-Emergency or Inpatient Setting (includes all patients
 except for those who were directly connected to an emergency department or inpatient
- 1007 encounter). We included (D) to account for the approximately 1/3 of patients who had no care
- setting connected to their positive test; patients may not have had a care setting if they had a test done in a drive-thru setting without an encounter or if the test was ordered in a virtual care
- 1009 done in a 1010 setting.
- 1010
- 1011
- Ц

1013 1014 1015 1016	S Fig 3. Monthly relative risks for testing positive for SARS-CoV-2 by Race in the Emergency Department, March 1, 2020 to January 31, 2022. These figures show the relative risks for testing positive by month and racial group in the emergency department; reference was White Race. Care settings are mutually exclusive.
1017	
1018	S Fig 4. Monthly Proportion of Patients Testing Positive for SARS-CoV-2 by Ethnicity and
1019	Care Setting
1020	These figures show the proportion of patients by month who were Hispanic, Not Hispanic, or
1021	had Missing Hispanic ethnicity information in the (A) Ambulatory, (B) Emergency Department,
1022	(C) Inpatient, and (D) Non-Emergency or Inpatient Setting (includes all patients except for those
1023	who were directly connected to an emergency department or inpatient encounter). We included
1024	(B) to account for the approximately 1/3 of patients who had no care setting connected to their
1025	positive test; patients may not have had a care setting if they had a test done in a drive-thru
1026	setting without an encounter or if the test was ordered in a virtual care setting.
1027	
1028	S Fig 5. Monthly relative risks for testing positive for SARS-CoV-2 by Ethnicity in the
1029	Emergency Department, March 1, 2020 to January 31, 2022.
1030	These figures show the relative risks for testing positive by month and ethnicity group in the
1031	emergency department; reference was White Race. Care settings are mutually exclusive.
1032	
1033	S Fig 6. Monthly Proportion of Patients Testing Positive for SARS-CoV-2 by Age and Care
1034	SettingSARS-CoV-2 +, Patients in Emergency Departments and Patients in the Non-
1035	Emergency or Inpatient Settings, Age by Month
1036	These figures show the proportion of patients by month and age group in the (A) Ambulatory,
1037	(B) Emergency Department, (C) Inpatient, and (D) Non-Emergency or Inpatient Setting
1038	(includes all patients except for those who were directly connected to an emergency department
1039	or inpatient encounter). We included (B) to account for the approximately 1/3 of patients who
1040	had no care setting connected to their positive test; patients may not have had a care setting if
1041	they had a test done in a drive-thru setting without an encounter or if the test was ordered in a
1042	virtual care setting.
1043	
1044	S Fig 7. Monthly relative risks for testing positive for SARS-CoV-2 by Age in the
1045	Emergency Department, March 1, 2020 to January 31, 2022.
1046	These figures show the relative risks for testing positive by month and age group in the
1047	emergency department; reference was 20-39-year-olds. Care settings are mutually exclusive.
1048	
1049	
1050	
1051	
1052	
1053	